Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

1	Prevalence of Neutralizing Antibodies against Adenoviruses types -C5, -D26 and -
2	B35 used in vaccination platforms, in Healthy and HIV-Infected Adults and Children
3	from Burkina Faso and Chad
4	Aline Raissa Ouoba', Océane Paris', Chatté Adawaye, Guy Takoudjou Dzomo,
5	Abderrazzack Adoum Fouda, Dramane Kania, Amidou Diarra, Zenaba Abdramane Kallo,
6	Isidore Tiandiogo Traore, Sodiomon Bienvenu Sirima, Edouard Tuaillon, Philippe Van de
7	Perre, Eric J. Kremer ² , Franck Jean Daniel Mennechet ²
8	@ Correspondence to: franck.mennechet@umontpellier.fr
9	Author affiliations: University of Montpellier, INSERM, EFS, Antilles University,
10	Montpellier, France (A.R. Ouoba, F.J. D. Mennechet, E. Tuaillon, P.Van de Perre);
11	University of Montpellier, CNRS, IGMM (O. Paris, E.J. Kremer, F.J.D. Mennechet);
12	Faculty of Human Health Sciences, N'Djamena, Chad (C. Adawaye); University Hospital
13	Complex "Le Bon Samaritain", N'Djamena, Chad (G.T. Dzomo); Toumaï University,
14	N'Djamena, Chad (A.A. Fouda, Z.A. Kallo); Sectoral AIDS Control Program, N'Djamena,
15	Chad (A.A. Fouda). Centre MURAZ, Bobo-Dioulasso, Burkina Faso (A.R. Ouoba, D.
16	Kania, I.T. Traore); Institute of Health Sciences, University of Nazi Boni, Bobo-Dioulasso,
17	Burkina Faso (I.T. Traore), National Institute of Public Health, Ouagadougou, Burkina Faso
18	(D. Kania). National Malaria Research and Training Center, Ouagadougou, Burkina Faso
19	(S.B. Sirima, A. Diarra); Health Action Research Group, Ouagadougou, Burkina Faso (S.B.
20	Sirima, A. Diarra).
21	These authors contributed equally to this study
22	² Co-senior authors

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

23 Article summary line: HAdVs Seroprevalence in Burkina Faso and Chad

- 24 Keywords: Vaccination, Adenovirus, HAdV-D26, HAdV-B35, Seroprevalence, Dendritic
- 25 Cells, Virus-derived vaccines, Burkina Faso, Chad, Alternative HAdV

26 Abstract

Vaccines derived from human adenoviruses (HAdV) are currently being used and trialed 27 against numerous infectious agents. However, pre-existing humoral immunity can impair 28 vaccines efficacy and safety. Strategies to circumvent this immunity often involve the use 29 of vectors with lower seroprevalence. We evaluated HAdV-C5, HAdV-D26 and HAdV-B35 30 seroprevalence from healthy and HIV-infected populations from Burkina Faso and Chad. 31 Seroprevalence for HAdV-C5 was high and comparable between countries (54%-66%), and 32 the highest in the HIV-infected groups from sub-Saharan regions (~90%). However, 33 compared to France (4%), seroprevalence for HAdV-D26 was significantly higher in sub-34 Saharan groups (~47%). By contrast, HAdV-B35 seroprevalence was low for all groups 35 tested. We also found that HAdV-D26 complexed with immunoglobulins induced strong 36 activation of dendritic cells in vitro. Our study fills gaps in the epidemiological data needed 37 to optimize HAdV-derived vaccines in sub-Saharan regions, and highlights the necessity to 38 better adjust vaccination strategies in Africa. 39

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

40 Introduction

Vaccines save millions of lives every year and limit major financial and public health 41 system losses (1). As of April 4th 2022, ~17% (25/153) of COVID-19 vaccines are viral 42 vector-derived (2). Among them, five are human adenovirus (HAdV) based, including 43 Convidecia (CanSino Biologics), Sputnik V (Gamaleya Research Institute), and the Johnson 44 & Johnson/Janssen (3). The most widely distributed COVID-19 vaccine is Vaszevria 45 (ChAdOx1-S), a chimpanzee adenovirus-derived vaccine developed by Oxford 46 University/AstraZeneca. HAdVs were among the first vectors developed for gene 47 transfer/vaccines. Among the ~100 ~HAdV types, HAdV species C type 5 (HAdV-C5) is 48 the best characterized and is the most widely used (4). 49

A drawback in the use of HAdV-derived vaccines is pre-existing immunity that impairs 50 vaccine efficacy and potential immunotoxicity (5,6). Current data suggest that both innate 51 and adaptive immune responses impact the duration of transgene expression from HAdVs 52 (7). Natural infection or the administration of AdV vectors in pre-immune subject results in 53 an activation of innate immune responses associated with the production of pro-54 inflammatory cytokines/chemokines, following by an adaptive immunity, including T and 55 B cell responses. Although HAdV-induced T cells are responsible for the lysis of cells 56 expressing viral and transgenic products (8), anti-HAdV Abs favor capsid uptake by 57 antigen-presenting cells through Fc receptors (9,10). HAdV-C5-based vaccines have 58 therefore shown an inverse correlation between efficacy/safety and pre-existing humoral 59 immunity. A better understanding of the interaction between innate and pre-existing 60 immunity, vaccines, is a major objective in the development of Ad-derived vaccines. 61

Several strategies have been deployed to bypass humoral immunity, including genetic and
chemical modifications of the capsid, generation of chimeric vectors, and the use of AdV

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

with low seroprevalence (6). Alternative candidates to HAdV-C5 are numerous, but only 64 HAdV-D26, -B35 and -E4 are currently in clinical trials/use (11). HAdV-D26-based 65 vaccines have been extensively tested in multiple clinical programs (12,13). Depending on 66 the trial, HAdV-D26-derived vaccines are generally used in prime-boost heterologous 67 strategies with the modified vaccinia Ankara or other HAdV types of such as HAdV-B35 68 or HAdV-C5. For COVID-19 vaccine, Ad26.COV2.S is a single dose (13), and Sputnik is 69 a heterologous vaccine using HAdV-D26 with -C5 in a prime-boost regimen (14). HAdV-70 B35 on other hand is not among candidates of COVID-19 vaccines, but has long been part 71 of the vaccination landscape for many infectious diseases, in particularly HIV (15), Ebola 72 virus (16), malaria (17) and tuberculosis (18), which are particularly devastating in sub-73 Saharan Africa. 74

While HAdV-C5 seroprevalence is well documented, data on HAdV-D26 and HAdV-B35 75 are less extensive (11). For HAdV-D26, accumulating evidence shows that seroprevalence 76 in Europe and North America rarely exceeds 10% (11,19). The few studies conducted on 77 the seroprevalence of HAdV-D26 in Africa have shown seroprevalence between 10 and 78 90%, with low or intermediate NAb titers compared to HAdV-C5 (20-22). For HAdV-B35, 79 seroprevalence is generally low worldwide, with rates slightly higher in some sub-Saharan 80 regions (11,23,24). However, global mapping of the seroprevalence of HAdV-D26 and 81 HAdV-B35 remains incomplete. These gaps make HAdV-derived COVID-19 vaccines less 82 predictable in populations that are globally more affected by infectious diseases. 83

In this study, we quantified HAdV-C5, -D26 and -B35 seroprevalence in individuals from
Burkina Faso and Chad. In contrast to Europe & North America, our study indicates that
HAdV-D26 seroprevalence is high, particularly in people living with HIV. By contrast,

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

- 87 HAdV-B35 seroprevalence is low in all the cohorts tested. Moreover, immunoglobulin-
- complexed HAdV-D26s stimulate the activation of human phagocytes.

89 Methods

90 Sample location and management

This cross-sectional study was conducted on 424 plasma samples from Burkina Faso (241), 91 Chad (93) & France (50) (Table 01). Samples were collected from adults or children, HIV-92 infected, or HIV-uninfected donors. Samples from HIV-uninfected subjects in Burkina Faso 93 were collected in 2012 at the National Malaria Research and Training Center (CNRFP) and 94 the Centre MURAZ in 2017. Collection and use of plasma samples for this study was 95 approved by institutional review boards of the CNRFP (AEP-04/07/20 1O/CIB-CNRFP) 96 and Institutional Ethic Committee of the Centre MURAZ (N°2017-361/MS/SG/CM/DG). 97 For Chad, HIV-uninfected samples were collected at the "Bon Samaritain" hospital (from 98 December 2018 to November 2019). In France, samples were provided by the French Blood 99 service (EFS, France) and the study was approved by the Occitanie & Midi-Pyrenees EFS 100 scientific board (EFS-OCPM: N°21PLER2019-0002). Samples from HIV-infected subjects 101 from Burkina Faso were randomly selected from the ANRS 12174 Promise-PEP trial sample 102 collection (20), in accordance with the sub-study request established and approved by 103 Institutional Ethic Committee of the country. For Chad, samples from HIV-infected subjects 104 were collected in 2019 at the Sectorial AIDS Control Program Center (PSLS) in the city of 105 N'Djamena. All samples were supported by a written and signed informed consent. 106

107 Adenoviruses, cells, and culture conditions

For neutralization assays, 911 cells were cultured as described previously (25). For *ex vivo*MoDC stimulation assay, blood was obtained from healthy adult donors via the EFS,
Montpellier, France and processed as previously described (26). GFP-expressing HAdVs

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

were amplified in (HEK) 293 or 911 cells and purified, and quantified as previously
described (27) Vector purity typically reached >99%. HAdV-D26-GFP was provided by
Dr. Eric Weaver (University of Nebraska-Lincoln, USA) and HAdV-B35-GFP by Andre
Lieber (University of Washington, Seattle, USA).

115 Adenovirus neutralization assays

For neutralizing antibody (NAb) titration tests, 911 cells were seeded at 10^s cells/well in 116 24-well plates and left to attach for 1 h. Plasma were diluted from 1:40 to 1:2160 and pre-117 incubated during 30 mins at 20°C with GFP-expressing-HAdV at 15, 100 or 500 pp/cell for 118 HAdV-C5, B35 and D26, respectively. As the seroprevalence of HAdV-B35 is typically 119 low, a pre-screening at 1:10, 1:100 and 1:1000 sample dilutions was performed to select 120 samples of interest. Two-fold dilutions of the HAdV of interest were systematically 121 included in duplicate to control the infectivity capacity of the vectors. HAdV standards, 122 controls, and samples were cultured with cells for 20 h at 37°C and 5% of CO₂. The next 123 day, the cells were collected and assayed for GFP expression by flow cytometry 124 (FACScalibur®- BD Bioscience or NovoCyte ACEA®- Agilent). The NAb titers was 125 quantified by identifying the sample dilutions that generate 50% of GFP+ cells. Samples 126 were considered positive when NAb triter \geq 100. Data analyses were performed using the 127 FlowJo software (BD Bioscience, France). 128

129 Immune complexes formation and DC stimulation

Monocyte-derived DCs (MoDCs) were challenged as previously described (9) using vectors
± plasma, plasma, LPS (500 ng/ml), or IVIg® (Baxter SAS, Guyancourt, France). Plasma
were pre-incubated individually with either HAdV-C5, D26 or B35 (at 1000 pp/cell) prior
to *in vitro* MoDC challenge. When appropriate, plasma were classified into four groups
according to their serological profile: (C5+, D26-), (C5+, D26-), (C5-, D26-) and (C5+,

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

139	Statistical analyses
138	manufacturer instructions (OptEIA human TNF ELISA Kit, BD Biosciences).
137	were collected after 14 h of culture and tested for TNF secretion by ELISA according to the
136	tested repeatedly on MoDCs generated from different blood donors (n=3 to 6). Supernatants
135	D26+) and pre-incubated with HAdV-C5 or D26 before the MoDC challenge. Plasma were

All data were analysed using GraphPad Prism 5 software. Statistical analyses were determined using non-parametric Mann Whitney U test when two groups are compared and Kruskal Wallis ANOVA analyses for multiples inter-group comparisons. The nonparametric Spearman test correlation test was used to evaluate the association between NAb titers and TNF levels (r_i (rho): Spearman rank correlation). Correlation tests were performed

145 with the online statistical tools for high-throughput data analysis (STHDA) (28).

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

146 **Results**

147 NAb titers for HAdV-C5, HAdV-D26, and HAdV-B35

We first evaluated the prevalence NAb in HIV-uninfected subjects from Burkina Faso, 148 Chad, and France (Figure 1 & 2B). Consistent with previous reports, the majority (60 ± 149 5%) of adults in all regions have HAdV-C5 NAbs, with median titers (IQR) of 643, 521 and 150 591 for Burkina Faso, Chad and France, respectively. For HAdV-D26, about 48% of 151 individuals from the African countries have NAb, whereas found no sample with NAb titers 152 \geq 1000 in the French group. The median NAb titers were 407, 333 and 30 for Burkina Faso, 153 Chad and France, respectively. By contrast, no sample showed significant titers for HAdV-154 B35 NAbs. 155

Individual NAb titers were stratified into three categories: ≤ 99 (negative or low), 100-999 156 (medium) and \geq 1000 (high) (Figures 2A & 2B). For HAdV-C5, 55%-66% of the African 157 subjects had titers \geq 100 and 22%-30% had Titers \geq 1000. In France, ~66% of the cohort 158 had NAb titers ≥ 100 and $\sim 18\%$ were ≥ 1000 . For HAdV-D26, $\sim 48\%$ of the individuals had 159 NAb titers \geq 100 in Burkina Faso and Chad, compared to only 4% in France. Additionally, 160 ~13% of the samples had high HAdV-D26 NAb titers in the sub-Saharan groups. 161 Seroprevalence was as follows (NAb threshold \geq 100): HAdV-C5 - 55% (143/261) and 162 HAdV-D26 - 48% (126/261) in Burkina Faso; HAdV-C5 - 63% (29/46) and HAdV-D26 -163 48% (22/46) in Chad, compared to HAdV-C5 - 66% (33/50) and HAdV-D26 4% (2/50) in 164 the French cohort (Figure 2B). 165

We found no samples with HAdV-B35 NAb titer greater than 100, and a seroprevalence < 6% for all groups tested (**data not shown**). Figure 2C shows the distribution of NAb titers among positive samples from Burkina Faso. NAb titres were stratified into three categories: low or moderate (100-499), medium (500-999) and high (\geq 1000). The majority of samples

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

exhibited medium (11%) or high (54%) NAb titers for HAdV-C5 (65% total), while most
of the cohort (58%) had low or moderate level of HAdV-D26 NAb. Nevertheless, 15% of
the positive samples had medium NAb titers to HAdV-D26, and 27% had NAb titers ≥ 1000
(42% total).

174 Correlation between NAb titers, sex, age, and HIV status in Burkina Faso

To better understand the natural history of HAdV infection among sub-Saharan populations, 175 we explored possible relationships between HAdV seroprevalence and gender. We found no 176 associations between single or dual-positive groups for HAdV-C5 and HAdV-D26 (Figure 177 S1A), and no differences in medians titer distribution according to sex (Figure S1B & C). 178 Assuming that HAdV type-specific NAb titers will wane over time, the comparison of 179 seroprevalence between different age groups also does not indicate an age-dependent 180 susceptibility to infections (Figure S2A) or the average NAb titers (Figure S2B). However, 181 seroprevalence for both HAdVs appears to increase overall with age, peaking in young 182 adults and maintained throughout life. 183

184 Immune-complexed (IC) HAdV-D26 activates MoDCs

We previously showed that IC-HAdV-C5 induces AIM2-associated pyroptosis in primary 185 cultures of human phagocytes (29,30). To evaluate the impact of IC-HAdV-D26, we 186 challenged MoDCs with plasma containing NAbs, preincubated with the respective HAdVs 187 and then quantified TNF secretion. We divided plasma into groups according to their 188 serological profile: single positive (HAdV-C5+/HAdV-D26-) and (HAdV-C5-/HAdV-189 D26+), dual positive (HAdV-C5+/HAdV-D26+) and dual negative (HAdV-C5-/HAdV-D26-190). We also ensured that groups had similar sampling and comparable mean NAb titers. The 191 HAdV-C5+/HAdV-D26- samples induced significantly higher production of TNF with 192 HAdV-C5 compared to HAdV-D26, whereas the opposite was observed with the HAdV-C5-193

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

/HAdV-D26+ plasma group (Figure 3A). The dual-positive group (HAdV-C5+/HAdV-D26+) induced significantly higher TNF production for both vectors in comparison to the dual-negative group (HAdV-C5-/HAdV-D26-). Additionally, TNF secretion for a given virus were comparable (regardless of the serological profile of the other virus).

Monotonic regression analyses to examine the correlation between HAdVs NAb titers and 198 the level of TNF secretion suggested modest correlation (r₂: 0.62 and 0.58) between the IC-199 HAdV-C5 and -D26 (Figure 3B). We then quantified the average production of TNF by 200 MoDCs, pre-incubated with each plasma individually, and independently of their 201 serological profile. This approach provides an overall estimate of the innate immune 202 response to the HAdVs in a given population. The average TNF secretion level was 203 significantly higher with HAdV-C5, followed by HAdV-D26 and HAdV-B35, respectively 204 (Figure 3C). Additionally, TNF secretion was significantly higher for HAdV-D26 205 compared with HAdV-B35. By contrast, MoDC activation with plasma from France (n=15) 206 was modest with HAdV-D26 and HAdV-B35 compared to HAdV-C5 (data not shown). 207

208 HAdV seroprevalence and MoDC TNF secretion according to HIV status

HIV is a major burden in sub-Saharan Africa and HAdV infections are common in people 209 with immunodeficiency, especially for HAdV-Ds, frequently isolated from 210 immunocompromised individuals. To determine wether HAdV seroprevalence is linked to 211 HIV status, we first evaluated the mean NAb titers in HIV-infected versus uninfected 212 controls (Figure 4A). For samples collected in Burkina Faso, mean NAb titers for HAdV-213 C5 only were significantly higher in the HIV-infected group. However, in Chad, this 214 increase was observed for the three HAdV tested. Of note, seroprevalence reached ~90% 215 for HAdV-C5 and HAdV-D26 and 24% for HAdV-B35, compared to 63%, 48%, and 0% for 216 uninfected controls (Figure 2B & 4A). In addition, HIV-infected subjects tended to have a 217

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

higher proportion of high NAb titers for both HAdV-C5 52% (25/46) and HAdV-D26 39%

219 (18/46) (data not shown) compared to the HIV-uninfected groups (Figure 2A).

Using IC-HAdVs (plasma + HAdVs) we then analysed the correlation between NAb titers 220 and TNF production by MoDC for samples collected from people HIV-infected and 221 222 uninfected individuals from Chad. In concordance with our previous observation (Figure 3B), we found a positive but moderate correlation (Figure 4C) that was higher when 223 plasmas where pre-incubated with HAdV-C5 compared to HAdV-D26. Finally, we 224 compared the ability of plasmas to induce TNF secretion from MoDCs according to their 225 HIV status. We found no difference in either of the HAdVs tested for stimulation between 226 the HIV-infected and uninfected groups (Figure 4D). However, we observed by comparison 227 that plasma samples incubated with HAdV-C5 or HAdV-D26 induced greater TNF levels 228 compared to HAdV-B35, regardless of the HIV status. No significant differences were found 229 between HAdV-C5 and HAdV-D26. For HAdV-B35, only the HIV-uninfected group 230 reached a significant variation compared with HAdV-D26. Finally, we observed that TNF 231 production was ~3-fold higher in samples from Chad compared to Burkina Faso, regardless 232 of HIV serologic profile and for all three HAdVs tested (Figure 3C & 4D). 233

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

234 Discussion

All vaccines, and in particular those derived from HAdVs, must be vetted judiciously (31). 235 We are just beginning to understand the biological mechanisms that govern the interactions 236 between pre-existing immunity, alarmins, coagulation factors and the effectiveness of 237 HAdV vectors (32). In addition to affecting the efficacy of the vaccine, the adverse events 238 of the STEP/Phambili trials from the HIV Vaccine Trials Network (HVTN) illustrate the 239 need to take precautions (33). In this study, we found high HAdV-C5 seroprevalences as 240 previously reported in other sub-Saharan regions (11,20-22). However, for HAdV-D26, 241 limited information was available. Our results on the French group confirmed a low HAdV-242 D26 seroprevalence in Europe (21). Investigations performed on rural populations from 243 other sub-Saharan African countries showed relative high prevalence and genetic diversity 244 among the species D of HAdV (HAdV-Ds) (34). This study also suggested that the fecal-245 oral transmission, hygiene measures, nutrition and local infectious burden play a role in 246 HAdV-Ds spread. 247

The majority of studies on HAdV-D26 or -B35 seroprevalence were conducted by 248 pharmaceutical companies to monitor the clinical applicability and of HAdV in a context of 249 vaccine development. We found a higher HAd-C5 and -D26 seroprevalence and mean NAb 250 titers in sub-Saharan cohorts compared to France (20-22). One study, however, found very 251 high NAb seroprevalence and titers for HAdV-D26 in cohorts from Cameroun, similar to or 252 higher than HAdV-C5 (19). These data also highlight the discrepancy between studies 253 regarding the level of HAdV-D26 seroprevalence in African cohorts. Taken together, these 254 studies showed that HAdV-D26 seroprevalence in sub-Saharan zone ranges from 45-88%. 255 However, the studies also generally showed that the proportion of people with a high NAb 256 titer (≥ 1000) for HAdV-D26 was low (3.4% overall with a maximum of 6.3% in South 257

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

Africa) (21,22,35). Within our groups, we found a relatively high proportion of individuals with HAdV-D26 NAb titers above those anticipated affecting the performance of a HAdVbased vaccines (**Figure 2C**). The proportion of samples having NAb titers \geq 1000 was the highest in the HIV-infected group from Chad, reaching ~40%.

HAdV-B35 seroprevalence was low for all groups tested (Figures 1A & 2A). Consistent
with other studies, seroprevalence for all HAdVs was independent of the donor's gender
(36). For the pediatric population, outcomes are sometimes contradictory, indicating either
lower seroprevalence compared to adults (36), or that infections/seroconversion occurred
relatively early in life, then waned with age (21,37). In our study, we found that NAb
serprevalence increased with age, but the mean NAb titer did not vary significantly (Figures
S2A & S2B).

HIV is a major burden in sub-Saharan Africa. In addition, HAdV infections are common in 269 people with immunodeficiency (38) and can cause significant morbidity, especially for 270 HAdV-Ds (39). Asymptomatic HAdV infections are also frequent in HIV-infected patients 271 who are not on antiretroviral therapy. However, most studies conducted on HAdV-C5 and 272 HIV status showed a comparable seroprevalence between HIV-infected and non-infected 273 individuals, which remains constant over the course of the progression to AIDS (40). For 274 HAdV-D26 or HAdV-B35, the correlation between HIV status and seroprevalence was 275 rarely described. Older studies showed that HAdV-B35 was preferentially isolated from 276 immunocompromised patients with AIDS (41), but did not indicate significant variations in 277 subjects from the United States or Africa, for both HAdV-D26 and HAdV-B35 (22,42). In 278 China, however, HAdV-D26 seroprevalence is higher in the population at high risk for HIV 279 infection than in the low risk cohort (43). In our study, HAdV-C5 seroprevalence was 280 significantly higher for the HIV-infected groups compared to the general population in 281

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

Burkina Faso and for all three HAdVs tested in Chad (**Figure 4A**). Despite numerous reports reflecting the importance of HAdV in patients with AIDS, the opportunistic role of this pathogen is poorly documented and, considering these data, may be underestimated in sub-Saharan Africa.

To better understand the consequences of HAdV NAbs, we used an ex vivo model based on 286 MoDC activation (9). With this system, we show consistent TNF secretion according to the 287 HAdV serological profiles (Figure 3A). However, some samples occasionally induced 288 MoDC activation even though they were HAdV-NAb negative/low. This observation was 289 confirmed by the moderate correlation observed between the NAb titers of the samples and 290 the level of MoDC activation (Figure 3B). We hypothesize that non-NAbs can form 291 complexes and activate MoDC. It has been established that HAdV humoral response is 292 directed against multiple capsid components (44). The dogma in the field suggests that 293 NAbs induced by HAdV natural infection lead to poor cross-reactivity, but this has not been 294 systematically analysed. In addition, studies have shown a probable cross-protection 295 between HAdVs from the same species (45,46). 296

We previously found that the amount of TNF secreted reflects the activation of the host 297 immune response and could therefore be indicative of vaccine efficacy. The Inflammatory 298 response induced by HAdV-D26 and HAdV-B35 are generally lower in comparison to 299 HAdV-C5, which correlates with the seroprevalence profiles observed for these populations 300 (Figure 3C). However, the differences between HAdVs were less evident for samples 301 collected in Chad (Figure 4D). Our analyses showed similar TNF production for all three 302 HAdVs in HIV-infected participants. The amount of TNF secreted by MoDC was also 303 higher in subjects from Chad compared to Burkina Faso in general. We presume the 304 possibility of numerous cross-reactions, or the involvement of other factors linked to 305

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

environment and exposure to infectious agents, but also to genetic variations, which may
influence the immune response to HAdVs-derived vaccines (47). In addition, several
extracellular proteins in plasma interact with HAdV and can increase the uptake by and
activation of DC (48).

310 Will HAdV-D26 or -B35-based vaccines prime individuals for infection by HIV? (49).

According to the vaccine manufacturers, there is no clinical evidence to date that pre-

existing immunity, whether natural or vector-induced, influences or blunts the efficacy of

HAdV-D26 or B35-derived vaccines (12). These studies suggested that the major difference

with HAdV-C5 could be explained by biological variables such as receptor usage (12).

However, we demonstrate that individuals with high HAdV-D26 NAb titers are common in 315 some sub-Saharan areas, with rates comparable to those of HAdV-C5. We found that plasma 316 from people HIV-infected + HAdV-C5 or HAdV-D26 can efficiently activate MoDC. Thus, 317 we share the concerns about the use of HAdV-based vaccines in sub-Saharan zones with 318 high HIV endemic populations (49,50). The risk/benefit assessment of HAdV-derived 319 vaccines must address HAdVs seroprevalence. We also recommend surveillance of de novo 320 HIV infections in high HIV-prevalent populations. In addition, our study underscores the 321 need to pre-evaluate the efficacy and safety of vaccines in sub-Saharan populations. These 322 recommendations are all the more important as we may be living through a crucial and 323 unique turning point in the history of vaccination, which could influence future strategies 324 to reduce vaccine hesitancy worldwide. 325

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

326 Acknowledgments

- 327 We thank Mehdi Taleb, Sofia Salazar Arenas, Chloé Houques, Lumen Ishimwe, Aboudou
- 328 Djobo, Lucas August, Marina Lavigne, Hiep Tran, Coraline Cheneau, TT Phuong Tran,
- 329 Karsten Eichholz, Karine Bollore et Jean Pierre Molès for reagents and technical help. We
- thank Thierry Gostan and Myriam Boyer for their help on statistical analyses and flow
- 331 cytometry, respectively. EJK is an INSERM fellow. We are grateful to Eric A. Weaver and
- Andre Lieber for the gift of HAdV-D26 and HAdV-B35, respectively.

333 Funding statement

This study was supported by the University of Montpellier (EJK), the Pierre Fabre Foundation (FJDM), the National Institute of Health and Medical Research (INSERM) (PVDP), The University Hospital Complex of Montpellier (ET), the University Hospital Complex "Le Bon Samaritain" (GTZ), the Centre MURAZ (ARO), and The French Ministry

338 of Higher Education (OP).

339 Declaration of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

342 Biographical Sketch of the first author

Dr Ouoba is a pharmacist and obtained a PhD in immunology/virology from the University of Montpellier, France. She works on diseases with epidemic potential at the Muraz research centre in Bobo Doulasso, Burkina Faso. Her main research interests are the detection and prevention of viral infections in sub-Saharan areas.

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

347 **References**

348	1.	Ehreth J. The global value of vaccination. Vaccine. 2003 Jan 30;21(7-8):596-600.
349	2.	WHO. Draft landscape and tracker of COVID-19 candidate vaccines [Internet]. 2021
350		[cited 2021 May 12]. Available from: https://www.who.int/publications/m/item/draft-
351		landscape-of-covid-19-candidate-vaccines
352	3.	Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020 Oct
353		1;586(7830):516–27.
354	4.	Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical
355		trials worldwide to 2017: An update. J Gene Med. 2018 May;20(5):e3015.
356	5.	Shirley JL, de Jong YP, Terhorst C, Herzog RW. Immune Responses to Viral Gene
357		Therapy Vectors. Mol Ther. 2020 Mar 4;28(3):709–22.
358	6.	Jönsson F, Kreppel F. Barriers to systemic application of virus-based vectors in gene
359		therapy: lessons from adenovirus type 5. Virus Genes. 2017 Oct;53(5):692-9.
360	7.	Gregory SM, Nazir SA, Metcalf JP. Implications of the innate immune response to
361		adenovirus and adenoviral vectors. Future Virol. 2011 Mar;6(3):357-74.
362	8.	Tang J, Olive M, Pulmanausahakul R, Schnell M, Flomenberg N, Eisenlohr L, et al.
363		Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins. Virology.
364		2006 Jul 5;350(2):312–22.
365	9.	Eichholz K, Bru T, Tran TTP, Fernandes P, Welles H, Mennechet FJD, et al.
366		Immune-Complexed Adenovirus Induce AIM2-Mediated Pyroptosis in Human
367		Dendritic Cells. PLoS Pathog. 2016 Sep;12(9):e1005871.

368	10.	Zaiss AK,	Vilaysane A,	Cotter MJ,	Clark SA, Me	eijndert HC,	Colarusso P,	et al.
		,		/			- /	

- 369 Antiviral antibodies target adenovirus to phagolysosomes and amplify the innate
- immune response. J Immunol. 2009 Jun 1;182(11):7058–68.
- 11. Mennechet FJD, Paris O, Ouoba AR, Salazar Arenas S, Sirima SB, Takoudjou
- Dzomo GR, et al. A review of 65 years of human adenovirus seroprevalence. Expert
- Rev Vaccines. 2019 Jun;18(6):597–613.
- 12. Custers J, Kim D, Leyssen M, Gurwith M, Tomaka F, Robertson J, et al. Vaccines
- based on replication incompetent Ad26 viral vectors: Standardized template with key
- considerations for a risk/benefit assessment. Vaccine [Internet]. 2020 Oct 3;
- 377 Available from:
- https://www.sciencedirect.com/science/article/pii/S0264410X20311609
- 13. Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al.
 Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J
- 381 Med. 2021 Jan 13;
- 14. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV,
- 383 Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-
- based heterologous prime-boost COVID-19 vaccine in two formulations: two open,
- non-randomised phase 1/2 studies from Russia. Lancet. 2020 Sep
- 386 26;396(10255):887–97.
- 15. Fuchs JD, Bart PA, Frahm N, Morgan C, Gilbert PB, Kochar N, et al. Safety and
 Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

389	in Adenovirus	s Serotype 5	Seronegative and	d Seropositive	Individuals. J	AIDS Clin
-----	---------------	--------------	------------------	----------------	----------------	-----------

- 390 Res. 2015 May;6(5).
- 16. Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, et al.
- Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass
- immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J

394 Virol. 2011/02/16 ed. 2011 May;85(9):4222–33.

- 17. Ockenhouse CF, Regules J, Tosh D, Cowden J, Kathcart A, Cummings J, et al.
- Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against

397 Sporozoite Challenge in Healthy Malaria-Naïve Adults. PLoS One.

398 2015;10(7):e0131571.

18. Churchyard GJ, Snowden MA, Hokey D, Dheenadhayalan V, McClain JB, Douoguih

400 M, et al. The safety and immunogenicity of an adenovirus type 35-vectored TB

401 vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350

402 cells/mm(3). Vaccine. 2015 Apr 8;33(15):1890–6.

Chen H, Xiang ZQ, Li Y, Kurupati RK, Jia B, Bian A, et al. Adenovirus-based
vaccines: comparison of vectors from three species of adenoviridae. J Virol.
2010/08/04 ed. 2010 Oct;84(20):10522–32.

406 20. Abbink P, Lemckert AAC, Ewald BA, Lynch DM, Denholtz M, Smits S, et al.

407 Comparative seroprevalence and immunogenicity of six rare serotype recombinant
408 adenovirus vaccine vectors from subgroups B and D. J Virol. 2007 May;81(9):4654–
409 63.

410	21.	Mast TC	Kierstead L.	Gup	ta SB.	Nikas A	A, I	Kallas E	EG.	Novitsky	V.	et al.
-			/									/

- 411 International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6,
- 412 type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and
- 413 implications for potential HIV vaccine trials. Vaccine. 2010 Jan 22;28(4):950–7.
- 414 22. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, et al.
- International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric
- 416 and adult populations. Vaccine. 2011 Jul 18;29(32):5203–9.
- 417 23. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Béthune MP, et
- 418 al. Replication-deficient human adenovirus type 35 vectors for gene transfer and
- 419 vaccination: efficient human cell infection and bypass of preexisting adenovirus
- 420 immunity. J Virol. 2003 Aug;77(15):8263–71.
- 24. Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D, et al. Prevalence of
 neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of
 The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol. 2004
 Mar;11(2):351–7.
- 25. Danthinne X, Werth E. New tools for the generation of E1- and/or E3-substituted
 adenoviral vectors. Gene Ther. 2000 Jan;7(1):80–7.
- Perreau M, Kremer EJ. Frequency, proliferation, and activation of human memory T
 cells induced by a nonhuman adenovirus. J Virol. 2005 Dec;79(23):14595–605.
- 429 27. Kremer EJ, Boutin S, Chillon M, Danos O. Canine adenovirus vectors: an alternative
 430 for adenovirus-mediated gene transfer. J Virol. 2000 Jan;74(1):505–12.

-51 20 , $1100000000000000000000000000000000000$	431	28.	Alboukadel Kassambara	. STHDA	Statistical	tools for	high-thro	ughput d	lata analy	vsis
--	-----	-----	-----------------------	---------	-------------	-----------	-----------	----------	------------	------

- 432 [Internet]. Available from: http://www.sthda.com/english/
- 433 29. Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5
- 434 immune complexes creates an improved environment for replication of HIV in T
- 435 cells. J Exp Med. 2008 Nov 24;205(12):2717–25.
- 436 30. Eichholz K, Bru T, Tran TTP, Fernandes P, Welles H, Mennechet FJD, et al.
- 437 Immune-Complexed Adenovirus Induce AIM2-Mediated Pyroptosis in Human
- 438 Dendritic Cells. PLoS Pathog. 2016 Sep 16;12(9):e1005871–e1005871.
- 439 31. Kremer EJ. Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines. Mol Ther.
 440 2020 Nov 4;28(11):2303-4.
- 441 32. Chéneau C, Eichholz K, Tran TH, Tran TTP, Paris O, Henriquet C, et al. Lactoferrin
- 442 Retargets Human Adenoviruses to TLR4 to Induce an Abortive NLRP3-Associated
 443 Pyroptotic Response in Human Phagocytes. Front Immunol. 2021;12:685218.
- 444 33. Fauci AS, Marovich MA, Dieffenbach CW, Hunter E, Buchbinder SP. Immunology.
 445 Immune activation with HIV vaccines. Science. 2014 Apr 4;344(6179):49–51.
- 446 34. Pauly M, Hoppe E, Mugisha L, Petrzelkova K, Akoua-Koffi C, Couacy-Hymann E,
- et al. High prevalence and diversity of species D adenoviruses (HAdV-D) in human
 populations of four Sub-Saharan countries. Virol J. 2014 Feb 11;11:25–25.
- 449 35. Ersching J, Hernandez MIM, Cezarotto FS, Ferreira JDS, Martins AB, Switzer WM,
- et al. Neutralizing antibodies to human and simian adenoviruses in humans and New-
- 451 World monkeys. Virology. 2010 Nov 10;407(1):1–6.

452	36.	Thorner AR,	Vogels R, Kas	spers J. Weverlin	g GJ, Holterman I	L. Lemckert AAC, et al
					,	-,,,,

- 453 Age dependence of adenovirus-specific neutralizing antibody titers in individuals
- 454 from sub-Saharan Africa. J Clin Microbiol. 2006 Oct;44(10):3781–3.
- 455 37. Ghasemi Y, Makvandi M, Samarbafzadeh AR, Nejati A, Najafifard S, Neisi N, et al.
- 456 Serotype determination of adenoviruses in children with respiratory infection. Indian
- 457 J Pediatr. 2014 Jul;81(7):639–43.
- 458 38. Al-Herz W, Moussa MAA. Survival and predictors of death among primary
- immunodeficient patients: a registry-based study. J Clin Immunol. 2012
- 460 Jun;32(3):467–73.
- 461 39. Lion T. Adenovirus infections in immunocompetent and immunocompromised
 462 patients. Clin Microbiol Rev. 2014 Jul;27(3):441–62.
- 463 40. Sun C, Zhang Y, Feng L, Pan W, Zhang M, Hong Z, et al. Epidemiology of
- adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in
 Guangzhou, southern China. Vaccine. 2011 May 17;29(22):3837–41.
- 466 41. De Jong PieterJ, Spigland I, Valderrama G, Horwitz MarshallS. Adenovirus Isolates
 467 from Urine of Patients with Acquired Immunodeficeincy Syndrome. The Lancet.
 468 1983 Jun 11;321(8337):1293–6.
- 469 42. Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, Helmus N, et al.
- Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a
- 471 vaccine vector. AIDS. 2004 May 21;18(8):1213–6.

472	43.	Zhang S, Huang W, Zhou X, Zhao Q, Wang Q, Jia B. Seroprevalence of neutralizing
473		antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus
474		type-68 in healthy Chinese adults. J Med Virol. 2013 Jun;85(6):1077-84.
475	44.	Yu B, Dong J, Wang C, Zhan Y, Zhang H, Wu J, et al. Characteristics of neutralizing
476		antibodies to adenovirus capsid proteins in human and animal sera. Virology.
477		2013;437(2):118–23.
478	45.	Kremer EJ. What is the risk of a deadly adenovirus pandemic? PLoS Pathog. 2021
479		Sep;17(9):e1009814.
480	46.	Russell KL, Broderick MP, Franklin SE, Blyn LB, Freed NE, Moradi E, et al.
481		Transmission dynamics and prospective environmental sampling of adenovirus in a
482		military recruit setting. J Infect Dis. 2006 Oct 1;194(7):877-85.
483	47.	Zimmermann P, Curtis N. Factors That Influence the Immune Response to
484		Vaccination. Clinical Microbiology Reviews [Internet]. 2019;32(2). Available from:
485		https://cmr.asm.org/content/32/2/e00084-18
486	48.	Chéneau C, Kremer EJ. Adenovirus-Extracellular Protein Interactions and Their
487		Impact on Innate Immune Responses by Human Mononuclear Phagocytes. Viruses.
488		2020 Nov 26;12(12).
489	49.	Buchbinder SP, McElrath MJ, Dieffenbach C, Corey L. Use of adenovirus type-5
490		vectored vaccines: a cautionary tale. Lancet. 2020 Oct 31;396(10260):e68-9.
491	50.	Logunov DY, Livermore DM, Ornelles DA, Bayer W, Marques E, Czerkinsky C, et
492		al. COVID-19 vaccination and HIV-1 acquisition. The Lancet. 2022
493		Apr;399(10333):e34–5.

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

494 Table

Regional Sample	Overall	Burkina Faso	Chad	France
		Bobo-dioulasso /Ouagadougou	N'Djamena	Montpellier
Number of Sample (%)	424 (100)	281 (66,3)	93 (21,9)	50 (11,8)
Sex, n (%, %)				
Male	154 (36,3)	107 (30,1)	35 (37,6)	12 (36)
Female	252 (59,5)	174 (69,9)	58 (62,4)	20 (26)
unknown	18 (4,2)	0	0	18 (38)
Age range,	7 months - 82 years	10 months - 82 years	7 months - 59 years	20 - 55 years
Mean Age	28,6 years	27,9 years	30,2 years	29,5 years
Age, year; n (%)				
(0-9)	48	37 (13,2)	11 (11,8)	0
(10-17)	51	49 (17,4)	2 (2,2)	0
(18-25)	100	62 (22,1)	21 (22,6)	17 (34)
(26-44)	131	78 (27,7)	43 (46,2)	10 (20)
(≥45)	75	55 (19,6)	15 (16,1)	5 (10)
Unknown	19	0	1 (1,1)	18 (36)
HIV status, n (%)				
Negative	358 (84,4)	261 (92,8)	47 (50,5)	50 (100)
Positive	66 (15,6)	20 (7,2)	46 (49,5)	0 (0)

495

496 **Table 01:** Demographics data

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

497 Figures



Figure 1: HAdV-C5, HAdV-D26, and HAdV-B35 NAb seroprevalence (bars: mean \pm SEM) in healthy individuals from Burkina Faso, Chad and France. Statistical analyses were performed by Kruskal Wallis non-parametric Anova statistical test. p values are denoted as: ns: not significant, *p < 0.05; ** p < 0.01; *** p < 0.001 and **** p < 0.0001.



503

Figure 2: Distribution of HAdV-C5 and HAdV-D26 NAb titers in healthy individuals from Burkina Faso, Chad and France. (A) NAb titers were arbitrarily stratified into the following categories: \leq 99, 100-999 and \geq 1000. (B) Percentage of positive samples (NAb titer \geq 100). (C) Distribution (percentage) of NAb titers among positive samples from Burkina Faso. NAb titer was divided into three groups: low (100-499), medium (500-999) and high (\geq 1000).

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad



```
509
```

Figure 3: TNF secretion was used as a surrogate for MoDC activation following in vitro 510 activation by various plasma from healthy individuals from Burkina Faso, pre-incubated with 511 HAdV-C5, HAdV-D26 or HAdV-B35. (A) Individual and average (mean ± SEM) TNF 512 secretion according to plasma serology profiles. Samples were classified into four groups: 513 (C5+ D26+); (C5- D26-); (C5- D26+); (C5+ D26+) and individually pre-incubated with 514 HAdV-C5 (\bullet) or HAdV-D26 (\blacksquare). Positive samples (NAb titer \geq 100). (**B**) Correlation 515 between plasma NAb titers and TNF secretion by MoDC. (C) Mean (with SEM) TNF secretion 516 by MoDC in presence of plasma individually pre-incubated with HAdV-C5, HAdV-D26 or 517 Comparisons were performed by Kruskal Wallis non-parametric ANOVA HAdV-B35. 518 statistical test. Correlation were performed with the non-parametric Spearman test. \mathbf{r}_{s} (rho) = 519 Spearman rank correlation. p values are denoted as: p < 0.05; p < 0.01; and p < 0.001. 520

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad



Figure 4: Overall HAdV-C5, HAdV-D26 and HAdV-B35 NAb titers and TNF secretion by 522 MoDC challenged with plasma from HIV-infected (HIV+) individuals or uninfected controls 523 (HIV-) from Burkina Faso or Chad, pre-incubated with various HAdVs. (A) Mean (with SEM) 524 NAb titers among HIV-infected and HIV-uninfected populations. (B) Percentage of positive 525 samples among HIV-infected subjects in Chad (NAb titer \geq 100). (C) Correlation between 526 plasma NAb titers and TNF secretion and (D) mean (with SEM) TNF secretion by MoDC 527 challenged with plasma from healthy or HIV+ groups from Chad, pre-incubated with HAdV-528 C5, HAdV-D26 or HAdV-35. Statistical analysis were made using Mann Whitney or Kruskal 529 Wallis ANOVA non-parametric tests for comparisons between two or multiples groups, 530 respectively. Correlations were made with the non-parametric Spearman test. r_{s} (rho) = 531 Spearman rank correlation. p values are denoted as: ns: not significant, p < 0.05; p < 0.01; 532 *** p < 0.001 and **** p < 0.0001. 533

521

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

534 Supplementary data





Figure S1: Overall HAdV-C5 and HAdV-D26 NAb titers among healthy individuals from Burkina Faso according to (**A**) single- or dual-positive groups (box-plots shows the minimum, first quartile, median, third quartile and maximum titer levels) and (**B**) gender groups (mean with SEM). (**C**) Distribution of NAb titers among males (n = 107) and females (n = 154) groups. NAb titers was stratified into 4 groups: negative (0-99), low (100-499), medium (500-999) and high (\geq 1000). Comparison was performed using the non-parametric Mann Whitney statistical test. ns: not significant, *p < 0.05; ** p < 0.01; *** p < 0.001.

543



Figure S2: NAb seroprevalence against HAdV-C5 and HAdV-D26 among different age groups
of healthy individuals from Burkina Faso. (A) Percentage of positive samples (NAb titer ≥
100) among different age groups for HAdV-C5 (Black bar) and HAdV-D26 (grey bar). (B)
Mean NAb seroprevalence (mean ± range) among different age groups of healthy positive
subjects from Burkina Faso. Comparisons were performed by Kruskal Wallis non-parametric
ANOVA statistical test.